Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis, cardiovascular disease, and cancer. Currently, physicians are limited to off-label therapies that have limited evidence to support prescribing. Consequently, there is a pressing need for new, effective drug treatments. In this report, hepatologists reveal what attributes drive their prescribing and what they are looking for in terms of efficacy, safety, and delivery from future treatments. Using the Target Product Profile (TPP) simulator, we can establish physicians’ preference for emerging drugs and assess if these drugs can capitalize on the untapped NASH space.
- How do hepatologists rate current NASH treatment options such as pioglitazone, vitamin E, and metformin?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- What trade-offs across different clinical attributes and price are needed from new NASH drugs to be preferred over current treatment options?
- How could emerging therapies like obeticholic acid meet the expectations of physicians treating NASH?
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European hepatologists and gastroenterologists fielded in April 2020
Key drugs: Vitamin E, metformin, pioglitazone, Ocaliva, GLP-1 receptor agonists, SGLT-2 inhibitors, statins, ursodeoxycholic acid
- Non-Alcoholic Steatohepatitis - Unmet Need - Detailed, Expanded Analysis (US & EU)
Author(s): Rohit Bansal, MS (Pharm.)
Rohit joined Decision Resources Group (DRG)’s Cardiovascular, Metabolic, Renal, and Hematologic Disorders team in April 2019. His current focus includes non-alcoholic steatohepatitis (NASH), glomerulonephritis, and renal anemia. Prior to joining DRG, Rohit worked as analyst helping pharmaceutical clients address their business questions across various therapeutic areas.
Rohit’s postgraduate research centred on molecular dynamics. His work included computer-aided drug design software that involved studying the effect of pharmaceutical excipients on the reabsorption of drug molecules from cancer cells leading to drug resistance.